Abstract
Introduction: The mucopolysaccharidoses (MPSs) are a group of rare genetic lysosomal disorders with progressive multisystem involvement. An MPS-specific physical symptom scale was developed and introduced a Physical Symptom Score (PSS) to quantify the somatic disease burden across MPS I, II and VI. Hypothesis: Somatic burden of disease in patients with attenuated MPS I, II and VI as measured by the PSS will be positively associated with age and negatively associated with neuropsychological functions [i.e. full scale intelligence quotient (FSIQ) and attention]. Materials and methods: Forty-eight patients with attenuated MPS I (n = 24), II (n = 14), and VI (n = 10) aged 6 to 32 years on enzyme replacement therapy who were enrolled in "Longitudinal Studies of Brain Structure and Functions in MPS Disorders" across seven centers. Somatic disease burden was measured by the PSS. Neuropsychological functions were measured by the Wechsler Abbreviated Scale of Intelligence (WASI) and Test of Variables of Attention (TOVA). Results: PSS was positively associated with age in attenuated MPS I (P < 0.001), MPS II (P < 0.01) and MPS VI (P < 0.05). There was a negative association of PSS with FSIQ in attenuated MPS I (P < 0.001) and in MPS VI (P < 0.001) but not with MPS II. Although attention scores were below average in all groups, a significant negative association between PSS and one measures of sustained attention (TOVA d prime) was found only in MPS VI. Conclusions: Physical Symptom Score increased with age in attenuated MPS I, II and VI, reflecting progressive somatic burden of disease despite treatment with enzyme replacement therapy. Furthermore, the association of increased somatic disease burden with decreased neurocognitive ability suggests that both measures reflect disease severity and are not independent.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 27-31 |
| Number of pages | 5 |
| Journal | Molecular Genetics and Metabolism Reports |
| Volume | 7 |
| DOIs | |
| State | Published - Jun 1 2016 |
Bibliographical note
Funding Information:The Lysosomal Disease Network (LDN) U54-NS065768, is a part of the National Institute of Health (NIH) Rare Diseases Clinical Research Network, supported through collaboration between the NIH Office of Rare Diseases Research at the National Center for Advancing Translational Science, the National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
We are thankful to Kathleen Delaney and Brianna Yund for their assistance with this research. We are very thankful for the support provided by the National MPS Society, Ryan Foundation for Orphan Disease Research and Center for Neurobehavioral Development (CNBD).
Funding Information:
This project was supported in part (Dr. Rudser) by the National Center for Advancing Translational Sciences, National Institutes of Health , through University of Minnesota-CTSI Grant Number NCATS UL1TR000114 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or CTSI.
Publisher Copyright:
© 2016 The Authors. Published by Elsevier Inc.
Keywords
- Enzyme replacement therapy
- Mucopolysaccharidosis (MPS)
- Neuropsychological measures
- Physical Symptom Score (PSS)
- Somatic disease burden